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• For patients suspected of having a testicular malignancy (that is, have a lump in the testis, doubtful epididymo-orchitis, or orchitis not resolving within two to three weeks), refer urgently for urological assessment within two weeks (D). An increasing tumour bulk is associated with more advanced disease, requiring more toxic treatment, with poorer outcomes. 6 • Abnormal masses in the epididymis are unlikely to be testicular tumours and do not require urgent referral.
Initial specialist management
• Preoperative investigations should include assay of tumour markers (α fetoprotein, human choriogonadotrophin, and lactate dehydrogenase, bilateral testicular ultrasonography, and chest radiography (D).
• After a germ cell tumour has been confi rmed, refer all patients to a specialist centre for the management of testicular tumours (D).
• For patients with metastases in whom the diagnosis is not in doubt (when there are high levels of tumour markers and a testicular mass on physical examination or ultrasound scan), immediate chemotherapy may be indicated. In such cases, perform a delayed orchidectomy either at the time of excision of residual masses or, for those patients who are not having additional surgery, after chemotherapy (GPP).
• When possible, perform an inguinal orchidectomy (D).
• Off er a testicular prosthesis to all patients (D).
• When appropriate, off er sperm storage to men who may require chemotherapy or radiotherapy (D).
• Involve clinical specialist nurses as early as possible in the management (GPP).
• Check serum markers before orchidectomy, 24 hours after, then weekly thereafter until concentrations are normal (GPP). Follow-up monitoring of serum α fetoprotein and human choriogonadotrophin concentrations is essential for non-seminomatous germ cell tumours (C), but lactate dehydrogenase concentrations have not been shown to be helpful in this context. • Owing to the rarity of testicular malignancy and its complex and potentially toxic treatments, ensure that the patient's general practitioner and other community services are well informed and involved throughout treatment and follow-up (GPP).
GUIDELINES
Management of adult testicular germ cell tumours: summary of updated SIGN guideline Testicular germ cell tumours are rare. In 2008, 203 new cases were diagnosed in Scotland, 1 with a crude incidence of 8.1 cases per 100 000 of the male population. 2 It is the 15th most common cancer among all men in Scotland 1 and the most common cancer in younger adult men. 3 It is one of the few curable solid cancers, even when it has metastasised, and has a crude overall fi ve year survival rate in Scotland of 95.8%. 1 Although the cure rate is high, the toxicity of treatment is substantial, resulting in treatment related deaths and long term adverse eff ects. Potential eff ects on employment and fertility are of particular importance in this age group.
This article summarises the most recent recommendations from the Scottish Intercollegiate Guidelines Network (SIGN) on the management of adult testicular germ cell tumours, 4 updating 1998 SIGN guidelines on this co ndition.
Recommendations
SIGN recommendations are based on systematic reviews of best available evidence. The strength of the evidence is graded as A, B, C, or D (fi gure), but the grading does not refl ect the clinical importance of the recommendations. Recommended best practice ("good practice points"), based on the clinical experience of the Guideline Development Group, is also indicated (as GPP).
Initial assessment and referral in primary care
• Presenting symptoms and history of patients with testicular cancer include 5 : -A painless, solid, unilateral mass in the scrotum (most cases) -Enlarged testicle -Scrotal pain (20% of cases) -Backache (11%) -Gynaecomastia (7%) -Dragging sensation in the scrotum -Incidental recent trauma (it is not thought that the trauma causes the cancer, but rather that it brings an existing tumour to the attention of the patient and physician).
• Examine patients presenting with a scrotal swelling carefully, and try to distinguish between lumps arising from the body of the testis and other intrascrotal swellings (GPP). To make the distinction, conduct ultrasonography if available (GPP). 
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for storage and before chemotherapy or any secondary treatment (GPP).
• If carcinoma in situ is diagnosed, discuss with the patient the options of surveillance, prophylactic orchidectomy, and testicular radiotherapy (D).
Clinical staging
• Use serum marker concentrations along with imaging techniques to determine the prognostic group (D).
• Contrast enhanced computed tomography of the thorax, abdomen, and pelvis is essential for staging (D).
• Complete and review all staging at a uro-oncology multidisciplinary team meeting no later than three weeks after surgery, but be aware that immediate postoperative scans may be misleading (GPP). Detailed recommendations on the management of stage I disease, metastatic disease, residual masses after chemotherapy, and treatment of relapsed disease are included in the full SIGN guideline.
4 Table 1 
Management of the contralateral testis
• For patients who are aged ≤30 years at diagnosis and who have a small (<12 ml) contralateral testis, consider biopsy of the contralateral testis to diagnose carcinoma in situ (C). About 5% of all men with testicular cancer have contralateral carcinoma in situ, 7 but the prevalence is much higher (34%) in those in this age group who have a small contralateral testis.
8
• When possible, perform contralateral testicular biopsy after all sperm samples have been obtained
Explanation of SIGN grades of recommendations
• At least one high quality meta-analysis, systematic review of randomised controlled trials, or randomised controlled trial with a very low risk of bias and directly applicable to the target population; or
• A body of evidence consisting principally of well conducted meta-analyses, systematic reviews of randomised controlled trials, or randomised controlled trials with a low risk of bias directly applicable to the target population, and demonstrating overall consistency of results
The grade of recommendation relates to the strength of the supporting evidence on which the evidence is based. It does not reflect the clinical importance of the recommendation A
• A body of evidence including studies rated as high quality systematic reviews of case-control or cohort studies, and high quality case-control or cohort studies with a very low risk of confounding or bias and a high probability that the relation is causal and which are directly applicable to the target population, and with overall consistency of results; or
• Extrapolated evidence from studies described in A B
• A body of evidence including well conducted case-control or cohort studies with a low risk of confounding or bias and a moderate probability that the relation is causal and which are directly applicable to the target population and with overall consistency of results; or
• Extrapolated evidence from studies described in B
C
• Non-analytic studies, such as case reports, case series, expert opinion; or
• Extrapolated evidence from studies described in C
D
Recommended best practice based on the clinical experience of the guideline development group
Good Practice Points (GPP) 
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Treatment of relapsed disease
After complete remission with chemotherapy for metastatic testicular cancer, relapse is highly unlikely in patients whose disease is associated with a good prognosis (<10%) but is more likely in patients with more advanced disease.
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Salvage treatment may be curative, and choice of treatment depends on several factors, including initial sensitivity to chemotherapy, tumour marker concentrations, and time to relapse. Treatments include further chemotherapy (which may be high dose with stem cell rescue) and surgery.
Late toxicity
• Potential short, medium, and long term eff ects of treatment include neurotoxicity, nephrotoxicity, pulmonary toxicity, and androgen defi ciency 11 ; the most serious late eff ects are the risk of second cancers and cardiovascular events.
• Oncologists should advise survivors of testicular cancer and their general practitioners of the increased risk of cardiovascular disease and of nongerm cell second malignancies (GPP). The latter risk is greatest for those treated before age 30 years and continues for more than 15 years after treatment.
• Advise survivors of testicular cancer not to smoke (C). No evidence was identifi ed to support routine cardiovascular screening in people with testicular cancer.
• Advise patients to remain vigilant for any unusual or "alert" symptoms, particularly relating to the gastrointestinal, respiratory, or urinary tracts, and to report these promptly to their general practitioners (GPP).
• Advise of the increased risk of haematological malignancies (especially after chemotherapy) and of solid malignancies in or near the fi elds of radiotherapy. Advise patients to report any alert symptoms to their general practitioners, who should have a low threshold for further investigation and appropriate referral to secondary care. Consider annual urine analysis for haematuria (GPP).
Follow-up after treatment
The aim is to detect relapse early, monitor and treat toxicity that is related to treatment, detect metachronous cancers, and off er support and counselling, particularly on issues such as employment and fertility. Follow-up protocols, including the frequency of clinic visits, blood tests, and radiology investigations, will vary according to tumour stage and are outlined in the full guidance.
Overcoming barriers
Rising incidence rates, improved treatment, and increased life expectancy result in a larger number of people living for many years after a diagnosis of testicular cancer, sometimes with serious sequelae. To most eff ectively prevent the onset of secondary disease and manage complications, patients should be advised of their increased risks and general practitioners should reinforce advice on healthy living at every opportunity. PRACTICE gen", "progestogen", "progestin", and "progestational [hormone or agent]", which were combined with search terms for miscarriage.
Four randomised trials were identifi ed. 2 -5 The quality of the four trials was poor (modifi ed Jadad quality scores ranged from 0/5 to 2/5 (table). Participant numbers were small even when the trials were combined in meta-analysis, with only 132 women treated with progesterone. Although all four trials showed a trend towards benefit, with a 42-69% reduction in rate of miscarriage, the confi dence intervals were wide and diff erences were not statistically Miscarriage is the commonest complication of pregnancy, occuring in one in six clinically recognised pregnancies. 1 Recurrent miscarriage is the loss of three or more consecutive pregnancies. Women with recurrent miscarriage (in contrast to women with sporadic miscarriage) tend to lose genetically normal pregnancies.
1 After comprehensive investigation, a cause for recurrent miscarriage is identifi ed in less than half of couples. 1 Most couples are therefore labelled as having unexplained recurrent miscarriage.
Progesterone, secreted by the corpus luteum and the placenta, has a central role in maintaining a pregnancy. 1 It is theoretically plausible that progesterone supplementation may reduce the risk of miscarriage in women with a history of recurrent miscarriages, and the fi rst trial using progesterone for such women was published in the BMJ in 1953. 2 This was followed over the decades by several small trials. However, uncertainty remains about the evidence: a survey we conducted in the United Kingdom in 2008 found that of the 102 obstetricians and gynaecologists who responded, 2% used progesterone routinely and 3% used it selectively; 90% called for a defi nitive placebo controlled randomised trial (unpublished data, AC and RR).
What is the evidence of the uncertainty?
We searched Medline, Embase, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, DARE (Database of Abstracts of Reviews of Eff ects), ISI proceedings, the International Standard Randomised Controlled Trial Number (ISRCTN) register, and the mRCT database for published and ongoing randomised trials. The search terms were "progesterone", "progesta-
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Does first trimester progesterone prophylaxis increase the live birth rate in women with unexplained recurrent miscarriages? ). Meta-analysis showed a statistically signifi cant reduction in miscarriages (fi gure). We found no evidence of statistical heterogeneity in the results (heterogeneity, P=0.94). Data were not available for other clinically relevant outcomes such as live birth. Our review fi ndings are consistent with the fi ndings of a Cochrane review on this subject, published earlier and including three of the above four studies. 6 Although the pooled analysis shows a statistically significant reduction in miscarriage rate, it is not surprising, given the poor quality of the trials (for example, none of them had evidence of allocation concealment), that most clinicians have called for a defi nitive placebo controlled randomised trial targeting live birth as the primary outcome.
Is ongoing research likely to provide relevant evidence?
We identifi ed ongoing studies from the ISRCTN register and the mRCT database. The results of a randomised study of oral dydrogesterone 20 mg a day versus placebo in women with recurrent miscarriages are awaited (clinical trial number: NCT00193674). Although the study is small (n=77) and the primary outcome is the cytokine ratio of interferon to interleukin 10, useful information on pregnancy outcome may emerge from this study.
We are currently recruiting participants for a large multicentre trial, funded by the UK's Health Technology Assessment programme, with the aim of providing a defi nitive answer to the question of whether progesterone prophylaxis in the fi rst trimester increases the live birth rate in women with unexplained recurrent miscarriages (box). The trial is expected to report in 2013.
What should we do in the light of the uncertainty?
The Royal College of Obstetricians and Gynaecologists' guideline on recurrent miscarriage 7 does not recommend progesterone for unexplained recurrent miscarriage. This view was endorsed by the vast majority of obstetricians and gynaecologists in our UK survey. Nonetheless, the existing evidence presents a powerful case for a randomised trial which should allow generation of robust recommendations for practice. Meta-analysis of trials of progesterone in recurrent miscarriage for the outcome of miscarriage A 22 year old student presents with a three day history of painful swollen left scrotum. He has also noticed a burning sensation when he passes urine.
10-MINUTE CONSULTATION
Epididymo-orchitis
What you should cover
There are three main diagnoses to consider in this patient. Epididymo-orchitis is the commonest cause of acute scrotal pain and refers to infl ammation of the epididymis and testis. However, the most important diff erential diagnosis that should be excluded is testicular torsion; this is a surgical emergency where prompt intervention is required. Trauma is an important diagnosis to think about in all patients and is usually suggested by the history. Two much rarer causes of acute scrotal pain and/or swelling include a rapidly growing testicular tumour, which in most cases will present as a painless testicular lump. Idiopathic scrotal oedema usually presents in childhood with bilateral oedema and bruising over the scrotal skin. The testes should not be tender on examination. 
Taking history
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• Sexual history: ask about recent changes in sexual partners and any associated symptoms such as urethral discharge • Recent viral illness: may point towards rarer causes such as mumps orchitis. Testicular swelling in mumps normally occurs 7-10 days after the characteristic fever and parotid swelling. Taking the patient's history is important to aid diagnosis and to help you decide the most likely pathogenesis. As there is a high incidence of sexually acquired infections in men under 35 these should be excluded in all cases. This 22 year old man is currently sexually active and is therefore at risk of a sexually transmitted pathogen, such as C hlamydia trachomatis or Neisseria gonorrhoea.
In patients with associated urinary symptoms and recent instrumentation (such as bladder catheterisation or cysto scopy) gram negative organisms such as Escherichia coli are the most likely cause. Mumps is a notifi able disease and is possible in those who have not been immunised. Rarer causes such as extra-pulmonary tuberculosis should be considered in those who are immunosuppressed.
What you should do
Perform a urine dipstick that includes a leucocyte esterase and nitrite test. Positive leucocytes, nitrites, and blood would point towards an underlying infection, but this fi nding is not diagnostic.
Urine should be sent for further microbiological analysis. First pass urine (the fi rst part of the urine the patient passes) is recommended when testing (nucleic acid a mplifi cation) for C trachomatis and N gonorrhoea . Patients should be instructed to collect the fi rst part of the urine they pass when giving a specimen. This urine specimen should also be sent for microscopy and c ulture.
As a rule, examine the scrotum with the patient in the standing position, and look for:
• Enlarged, erythematous scrotum • Tenderness to palpation of the testis, epididymis, or the cord on the aff ected side • In early presentations of epididymo-orchitis the epididymis may be tender and thickened • In later stages of epididymo-orchitis the entire hemi-scrotum may be oedematous. 
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It may be diffi cult to diff erentiate between epididymoorchitis and testicular torsion on clinical examination. In torsion, the testis will be very tender whereas, typically in epididymo-orchitis, elevating and supporting the scrotum with the patient standing may reduce their pain.
However, if there is any doubt in diagnosis, the patient should be referred immediately for surgical exploration.
Treatment
• If testicular torsion is suspected, refer the patient urgently for surgical exploration • If the diagnosis is epididymo-orchitis, advise about appropriate rest and analgesia • Give empirical antibiotics in all patients with epididymo-orchitis. The preferred antibiotic regimen depends on history and whether a sexually acquired micro-organism is likely (fi gure). Once treatment has been started, advise all patients to attend the genitourinary medicine department for further investigations and anonymous partner tracing.
Ask patients to return if there is no improvement within 72 hours. The scrotal swelling could take up to six weeks to resolve completely, but after 3-5 days of antibiotics the pain should be substantially better and the scrotum should be less erythematous. If no improvement occurs, exclude a scrotal abscess through referral to an on call urologist for assessment with clinical and radiological examination.
UK National Guidelines recommend further investigation of the urinary tract in patients with confi rmed gram-negative enteric organisms (box). Further investigation is strongly advised in patients older than 50 years. In patients with recurrent infections and prostatic symptoms the clinical suspicion of an underlying obstruction should be higher. Adopt a lower threshold for urology referral for these patients.
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